Growth Metrics

Summit Therapeutics (SMMT) Amortization (2016 - 2020)

Summit Therapeutics filings provide 7 years of Amortization readings, the most recent being -$7.4 million for Q1 2020.

  • Quarterly Amortization fell 192.73% to -$7.4 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was -$52.7 million through Mar 2020, down 1081.03% year-over-year, with the annual reading at $79.9 million for FY2019, N/A changed from the prior year.
  • Amortization hit -$7.4 million in Q1 2020 for Summit Therapeutics, up from -$46.9 million in the prior quarter.
  • Across five years, Amortization topped out at $59.8 million in Q1 2019 and bottomed at -$91.6 million in Q1 2017.
  • Average Amortization over 5 years is $11.2 million, with a median of $16.3 million recorded in 2016.
  • The largest annual shift saw Amortization surged 665.68% in 2016 before it tumbled 395.21% in 2017.
  • Summit Therapeutics' Amortization stood at $47.3 million in 2016, then crashed by 99.31% to $325393.4 in 2017, then tumbled by 3855.3% to -$12.2 million in 2018, then tumbled by 283.87% to -$46.9 million in 2019, then skyrocketed by 84.12% to -$7.4 million in 2020.
  • Per Business Quant, the three most recent readings for SMMT's Amortization are -$7.4 million (Q1 2020), -$46.9 million (Q4 2019), and $32.4 million (Q4 2019).